We are excited to kick off the new year with the release of our latest research article, titled “Isolation and Characterization of Neutralizing Monoclonal Antibodies Against RBD of the SARS-CoV-2 Spike Protein.”
Despite the success of monoclonal antibodies (mAbs) against Covid-19, the persistent evolution of the virus demands continuous innovation because the available antibodies are no longer as effective as they once were.
In this study, we pioneered innovative approaches, combining genetic immunization for rapid antibody production and the potent immune stimulation enabled by protein vaccination. This resulted in a diverse pool of antibodies, each exhibiting unique binding and neutralizing specificities.
Our panel of mAbs, rigorously tested through ELISA, BLI, and FACS, shows efficacy against SARS-CoV-2 variants, including the latest Omicron strains (BA.1 and BA.5).
Importantly, these antibodies demonstrate flexibility to adapt to emerging variants, offering promise in addressing both current and future SARS-CoV-2 infections.
This significant result would not have been possible without the hard work and dedication of our exceptional researchers Alessia Muzi and Emanuela D’Acunto, together with all the other authors, to whom we extend special thanks for their contribution.
We invite you to read the full paper here: https://lnkd.in/dvzfJvaR
We’re eager for this to mark the beginning of a series of achievements and successes in 2024!
